Mayo Clinic launches new technology platform ventures to revolutionize diagnostic medicine
- April 14, 2021
ROCHESTER, Minn. — Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster and more accurate diagnoses and provide truly continuous care to patients. The Remote Diagnostics and Management Platform (RDMP) connects data with innovative new artificial intelligence (AI) algorithms and augments human decision-making within existing clinical workflows. RDMP enables “event-driven medicine,” providing insights in the right context, at the right time.
“The dramatically increased use of remote patient telemetry devices coupled with the rapidly accelerating development of AI and machine learning algorithms has the potential to revolutionize diagnostic medicine,” says John Halamka, M.D., president, Mayo Clinic Platform. “With RDMP, clinicians will have access to best-in-class algorithms and care protocols and will be able to serve more patients effectively in remote care settings. The platform will also enable patients to take more control of their health and make better decisions based on insights delivered directly to them.”
Mayo Clinic has launched two new companies, with partners, to support the newly created RDMP.
Anumana Inc. to develop and commercialize AI-enabled algorithms
Mayo Clinic and AI-driven health technology company nference have formed Anumana Inc. to create and bring to market innovative digital sensor diagnostics by applying nference AI to Mayo’s deep repository of medical data. Anumana will focus initially on designing state-of-the-art neural network algorithms based on billions of relevant pieces of heart health data in Mayo Clinic’s Clinical Data Analytics Platform, including raw electrocardiogram (ECG) signals, to unlock hidden biomedical knowledge and enable early detection as well as accelerate treatment of heart disease.
Journalists: Broadcast-quality sound bites with Dr. Halamka and Dr. Friedman are available in the downloads at the end of the post. Please courtesy: “John Halamka, M.D. / president, Mayo Clinic Platform” and “Paul Friedman, M.D. / chair Cardiology, Mayo Clinic in Rochester.”
“Undiagnosed heart disease affects millions of Americans and people across the globe,” says Paul Friedman, M.D., chair of the Department of Cardiovascular Medicine at Mayo Clinic in Rochester, who led the team that developed the algorithms. “For many conditions, such as a weak or thickened heart pump, or silent arrhythmias, effective evidence-based treatments exist that can prevent heart failure, stroke, or death. The key is to detect the disease before symptoms develop to prevent these events from happening. The addition of AI to the ECG, a ubiquitous and inexpensive point-of-care test that is already integrated into medical workflows, makes this approach good for patients, convenient for clinicians, and massively scalable.”
“ECGs have been read and notated manually by physicians for more than a century,” says Murali Aravamudan, co-founder and CEO of nference and CEO of Anumana. “Our augmented intelligence technology, in the hands of scientific and clinical experts, will enable a comprehensive translation of the language of the heart. We think of it as the Rosetta Stone for cardiac medicine.”
Lucem Health Inc. to collect, orchestrate, and curate data from any device
Mayo Clinic and Commure, a General Catalyst portfolio technology company that helps innovators accelerate delivery of next-generation health care experiences, launched Lucem Health Inc., to provide the overall platform for connecting remote patient telemetry devices with AI-enabled algorithms, including those developed by Anumana and Mayo Clinic, and for integrating diagnostic insights generated by these algorithms into clinical workflows. Lucem’s platform collects, orchestrates, and curates data from virtually any device; hosts and supports AI/ML runtime algorithms; and delivers application development frameworks and services for workflow integration.
“Lucem Health exists to help diagnostic medicine innovations see the light of day,” says Sean Cassidy, founding CEO of Lucem Health. “We are excited to work with partners like Mayo Clinic and Anumana that are reimagining how we detect and treat diseases.”
Today’s announcement is the latest advancement in Mayo Clinic Platform’s development of an ecosystem of partners and capabilities that complement Mayo’s clinical capabilities and provide access to scalable solutions. Mayo Clinic Platform is a coordinated portfolio approach to create new platform ventures and leverage emerging technologies, including AI, connected health care devices and natural language processing.
Anumana completed $25.7 million in Series A financing led by founders nference and Mayo Clinic along with Matrix Capital Management, Matrix Partners, and NTTVC. Anumana will use the investment to fund further development and commercialization of AI-enabled ECG and multimodal algorithms for clinical care.
Lucem Health completed $6 million in Series A financing led by founders Mayo Clinic and Commure. Lucem Health will use the investment to build out its platform for serving AI-generated diagnostic insights to the point of care.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. For information on COVID-19, including Mayo Clinic’s Coronavirus Map tracking tool, which has 14-day forecasting on COVID-19 trends, visit the Mayo Clinic COVID-19 Resource Center.
Anumana is a health technology company from Mayo Clinic and nference that catalyzes Mayo Clinic medical insight with leading-edge nference scientific expertise to develop and commercialize innovative applications for early disease detection. Visit anumana.ai.
About Lucem Health
Lucem Health is helping to revolutionize diagnostic medicine. Its platform connects remote patient telemetry and biosensing devices with advanced, diagnostic-focused artificial intelligence algorithms and generates insights that enable clinicians to provide more effective continuous care and empower consumers to have better control of their health and well-being. For more information, email firstname.lastname@example.org.
- Duska Anastasijevic, Mayo Clinic Public Affairs, email@example.com